Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749360 | 0.83 | L3MBTL1 (0.45) | TSHRMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL6064161 | 0.83 | CYP1A2 (0.60) | MEN1KMT2AALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL7372704 | 0.82 | NPC1 (0.54) | TSHRKMT2AALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL5693370 | 0.80 | NPSR1 (0.50) | MEN1KMT2AALDH1A1CYP1A2L3MBTL1 | |
| SCHEMBL6063382 | 0.80 | PTGER4 (0.48) | MEN1KMT2APTGER4 | |
| SCHEMBL5750409 | 0.79 | CYP1A2 (0.46) | KMT2AALDH1A1CYP1A2L3MBTL1CYP2C9 | |
| SCHEMBL24294928 | 0.78 | KDM4E (0.47) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6898388 | 0.77 | KMT2A (0.45) | TSHRMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL2086658 | 0.76 | CASP1 (0.47) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4449431 | 0.72 | PTGER4 (0.57) | ALDH1A1CYP1A2L3MBTL1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060717-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-6949573-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1476158-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | TSHR 4618/4885MEN1 3563/4885KMT2A 2770/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | TSHR 1526/4885MEN1 3795/4885KMT2A 2623/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | TSHR 4618/4885MEN1 3563/4885KMT2A 2770/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | TSHR 4618/4885MEN1 3563/4885KMT2A 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.